Alireza M. Rezakhanlou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alireza M. Rezakhanlou has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Beibei Zhai
Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
40 shared publications - Colin Collins
Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada
40 shared publications - Dennis Brown
Rakovina Therapeutics, Vancouver, British Columbia, Canada
40 shared publications - Fariba Ghaidi
Vancouver Prostate Centre, Vancouver, British Columbia, Canada
40 shared publications - Hans Adomat
Vancouver Prostate Centre, Vancouver, British Columbia, Canada
40 shared publications - Htoo Zarni Oo
Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
40 shared publications
Latest Publications
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicates of cell cycle assays and statistics
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicates of cell cycle assays and statistics
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Material and Methods S1 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Materials and methods for in vivo toxicity and cellular fluorescence assays
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Material and Methods S1 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Materials and methods for in vivo toxicity and cellular fluorescence assays
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicate graphs of spheroid assays and cell fluorescence data
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicate graphs of spheroid assays and cell fluorescence data
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicate data of DNA damage assays
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicate data of DNA damage assays
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicate graphs of cell viability assays and comparison of cell viability assay methods
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicate graphs of cell viability assays and comparison of cell viability assay methods
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicate graphs of HDAC, PARP1, PARP2 and PARylation assays
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Replicate graphs of HDAC, PARP1, PARP2 and PARylation assays
- Open Access
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Blood cell panel counts and weight loss percentage of in vivo toxicity study
- 25 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from A Bifunctional PARP-HDAC Inhibitor with Activity in Ewing Sarcoma
Blood cell panel counts and weight loss percentage of in vivo toxicity study
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from A bi-functional PARP-HDAC inhibitor with activity in Ewing sarcoma
Replicate data of DNA damage assays
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from A bi-functional PARP-HDAC inhibitor with activity in Ewing sarcoma
Replicate data of DNA damage assays
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from A bi-functional PARP-HDAC inhibitor with activity in Ewing sarcoma
Replicate graphs of cell viability assays and comparison of cell viability assay methods
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from A bi-functional PARP-HDAC inhibitor with activity in Ewing sarcoma
Replicate graphs of cell viability assays and comparison of cell viability assay methods
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from A bi-functional PARP-HDAC inhibitor with activity in Ewing sarcoma
Replicate data of DNA damage assays
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from A bi-functional PARP-HDAC inhibitor with activity in Ewing sarcoma
Replicate data of DNA damage assays